Summary
Report Scope:
The scope of this study entails the worldwide market for targeted therapeutics. The report covers the entire market for targeted therapeutics, which incorporates two main types, small molecules and monoclonal antibodies. Based on application, targeted therapeutics is divided into lung cancer, breast cancer, blood cancer, colorectal cancer and others.
By geography, the market has been divided into four regions: North America, Europe, Asia-Pacific and the Rest of the World. Detailed analyses of major countries: the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered. For market estimates, data has been provided for the year 2020 as the base year, with forecasts for 2021-2026. Estimated values are based on drug manufacturer total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
- 24 data tables and 29 additional tables
- An overview of the global market for targeted therapeutics within the biopharmaceuticals sector
- Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation of current market size and market forecast for targeted therapeutics, technological advancements, and corresponding market share analysis by type, application and geographic region
- Detailed description of the target-specific functionality, advantages of target therapeutics, their production and processes, and discussion on their ability to provide therapeutic treatments for various chronic diseases
- Coverage of disease and economic burden of cancer, types of cancer therapy and insights into cancer treatment strategy timeline
- Insight into global R&D activities related to oncology drugs, industry structure, product launches, clinical trials, and regulatory scenario affecting the future marketplace
- Competitive landscape and pipeline analysis of the key companies operating in the global market, their company share analysis, and relevant oncology drug licensing deals and M&A deals
- Company profiles of major industry players, including Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), F. Hoffmann-La Roche Ltd., Pfizer, Novartis, Merck & Co., and Takeda Pharmaceutical Co., Ltd.
ページTOPに戻る
Table of Contents
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Intended Audience
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Market Size and Evolution
Chapter 3 Market Overview
Cancer Burden
Causes of Cancer
Genetic Factors
Lifestyle Factors
Environmental Factors
Cancer-Causing Genes
Immune System and Cancer
Cancer Prevention
Types of Cancer Treatment
Non-pharmacological Approaches
Pharmacological Approaches
Gene Therapy
Market Dynamics
Drivers
Restraints
Opportunity
Chapter 4 Impact of COVID-19 on Market
Overview
Current Outlook
Impact of COVID-19 on Cancer Care
Chapter 5 Regulatory Aspects
Overview
United States
New Drug Application (NDA)
Fast-Track Status
Europe
Japan
India
New Drug Approval
Import Registration Certificate
Import License
China
Chapter 6 Market Breakdown by Type of Targeted Therapy
Overview
Small Molecules
Market Size and Forecast
Market Analysis
Monoclonal Antibodies
Market Size and Forecast
Market Analysis
Chapter 7 Market Breakdown by Application
Overview
Lung Cancer
Market Size and Forecast
Market Analysis
Breast Cancer
Market Size and Forecast
Market Analysis
Blood Cancer
Market Size and Forecast
Market Analysis
Colorectal Cancer
Market Size and Forecast
Market Analysis
Other Cancers
Market Size and Forecast
Market Analysis
Chapter 8 Market Breakdown by Region
Introduction
North America
Market Analysis
U.S.
Canada
Europe
Market Impact
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
Market Analysis
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 9 Industry Structure
Company Landscape
Pipeline Analysis
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
Chapter 10 Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
MERCK & CO., INC.
NOVARTIS AG
PFIZER
TAKEDA PHARMACEUTICAL CO., LTD.
Chapter 11 Appendix: Acronyms